News

Novo Nordisk's CFO sceptical Trump executive order on drug manufacturing can cut timelines
Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to ...
Novo Nordisk shares are rising after the company cut its outlook. It’s been that kind of year.
Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...
Pharmaceutical Technology42m
Novo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demand
Novo Nordisk has cut its sales and profits forecasts for 2025 due to lower demand in the US for blockbuster weight loss and ...
Novo Nordisk shares up on hopes for US Wegovy recovery after forecasts cut
Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday for the first time since the launch of its Wegovy ...
NJBIZ14h
Novo Nordisk seeks FDA approval for Wegovy weight loss pill
Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...
Trending tickers: AMD, Novo Nordisk, Rivian, Super Micro and Trainline
Novo Nordisk (NVO, NOVO-B.CO) said first-quarter sales of its first-to-market weight-loss drug Wegovy were 17.36bn Danish ...
The Manila Times23h
Novo Nordisk A/S: ECO 2025 - Novo Nordisk semaglutide data shows new health benefits across serious chronic diseases
Semaglutide is marketed under the brand names Wegovy ® (once-weekly semaglutide 2.4 mg injection), Ozempic ® (once-weekly ...